Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. (Q40449831)

20 September 2017

Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. (English)

1 reference

20 September 2017

1 reference

1 reference

Laundette P Jones

1

1 reference

20 September 2017

Minglin Li

2

1 reference

20 September 2017

Ewa D Halama

3

1 reference

20 September 2017

Yongxian Ma

4

1 reference

20 September 2017

Ronald Lubet

5

1 reference

20 September 2017

Clinton J Grubbs

6

1 reference

20 September 2017

Chu-Xia Deng

7

1 reference

20 September 2017

Eliot M Rosen

8

1 reference

20 September 2017

Priscilla A Furth

9

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

20 September 2017

1 reference

20 September 2017

24

1 reference

20 September 2017

22

1 reference

20 September 2017

3554-3562

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1208426

20 September 2017

0 references

cites work

Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Estrogen receptors alpha and beta in the rodent mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Role of direct interaction in BRCA1 inhibition of estrogen receptor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Selective estrogen receptor modulation: concept and consequences in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Tamoxifen flare in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Chemoprevention of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208426

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208426

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference